BGE-102 cuts hsCRP 86% at day 14 in obese adults with raised inflammation; 93% reach normal levels

BioAge Labs/BGE-102 (NLRP3)

In a Phase 1 multiple-dose cohort, BioAge's oral NLRP3 inhibitor BGE-102 at 120 mg daily cut hsCRP by 86% at day 14, with 93% of participants achieving levels below 2 mg/L within a week.

• 86% median hsCRP reduction at day 14; 93% (13 of 14) reached <2 mg/L (cardiovascular risk threshold) by day 7.
• Secondary biomarkers: 44% IL-6 reduction, 30% fibrinogen reduction, 93% IL-1β suppression in ex vivo assays.
• Well tolerated across all doses with infrequent mild-to-moderate adverse events; no dose-limiting toxicities.